Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Annales De Pathologie|January 19, 2016
[Strategy for molecular testing in pulmonary carcinoma]Frédérique Penault-Llorca, Lucie Tixier, Loïc Perrot, et al.
World Journal of Gastrointestinal Surgery|March 28, 2014
Giant mucinous cystic adenoma with pancreatic atrophy mimicking dorsal agenesis of the pancreasJohan Gagnière, Aurélien Dupré, David Da Ines, et al.
World Journal of Gastroenterology|May 21, 2013
Massive hepatic necrosis with toxic liver syndrome following portal vein ligationAurélien Dupré, Johan Gagnière, Lucie Tixier, et al.
Plos One|February 10, 2016
Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control StudyBertrand Le Roy, Lucie Tixier, Bruno Pereira, et al.
BMC Cancer|February 4, 2018
Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situMarie Beguinot, Marie-Melanie Dauplat, Fabrice Kwiatkowski, et al.
Expert Review of Molecular Diagnostics|October 31, 2023
Usefulness of an RNA extraction-free test for the multiplexed detection of ALK, ROS1, and RET Gene Fusions in Real Life FFPE Specimens of Non-Small Cell Lung CancersFrancesca Damiola, Laurent Alberti, Audrey Mansuet-Lupo, et al.
Breast Cancer Research and Treatment|March 7, 2024
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trialAngeline Ginzac, Ioana Molnar, Xavier Durando, et al.
Annales De Pathologie|August 16, 2021
[2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France]Camille Franchet, Lounes Djerroudi, Aurélie Maran-Gonzalez, et al.
Pageof 1